Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251

Journal of Clinical Pharmacology

Volumn 41, Issue 10, 2001, Pages 1091-1097

  Aweeka, F ^a   Trapnell, C ^a   Chernoff, M ^a   Jayewardene, A ^a   Spritzler, J ^a   Bellibas, S E ^a   Lizak, P ^a   Jacobson, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; THALIDOMIDE;

ADULT; APHTHOUS ULCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ULCER HEALING;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENTS; STATISTICS, NONPARAMETRIC; STOMATITIS, APHTHOUS; THALIDOMIDE;

EID: 0034833848     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012698     Document Type: Article

References (18)

1. Thalidomide: A surprising recovery
2. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
3. Tumor necrosis factor functions in an autocrine manner in the induction of human immunodeficiency virus expression
4. Disposition of thalidomide in rabbits and rats
5. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species
6. Hydroxylated metabolites of thalidomide: Formation in-vitro and in-vivo in man
7. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
8. Metabolism of thalidomide in human microsomes, cloned human cytochrome P450 isozymes, and Hansen's disease patients
9. Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450
10. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene
11. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
12. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects
13. Single dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers
14. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone
15. Determination of thalidomide in plasma and blood by HPLC, avoiding hydrolytic degradation
16. Noncompartmental pharmacokinetics